Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Phase 3XIAFLEXPositive

AI Analysis

Summary

Keenova has dosed the first patient in a Phase 3 trial evaluating XIAFLEX (collagenase clostridium histolyticum) for hammer toe treatment, marking the first registered, randomized Phase 3 study for a nonsurgical therapy in this indication.

Clinical Trial Data

Phase

Phase 3

Outcome Details

First patient dosed in Phase 3 trial

Importance:6/10

Sentiment:

0.60

Phase 3XIAFLEXhammer toeclinical trialfirst patient dosednonsurgical therapy

Related Companies

$TRAX

Read the original article

Published by PR Newswire Pharma on August 20, 2026 11:30 AM

Read Original